-
Mashup Score: 0
Opioid use disorder medication remains underused, and cost appears to contribute, studies show
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Opinion | Why Isn't Buprenorphine Available at All Pharmacies? - 9 month(s) ago
More access to this life-saving medication is essential
Source: www.medpagetoday.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Study: Buprenorphine for OUD unavailable at many pharmacies - 10 month(s) ago
About 58% of pharmacies reported availability of buprenorphine for opioid use disorder at the time of patients’ requests, according to researchers.Prior research has suggested that pharmacists play a critical role in providing effective and consistent care for opioid use disorder (OUD). One study found that pharmacy-based care was associated with higher rates of retention in OUD treatment
Source: www.healio.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1Wolters Kluwer Health - 10 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Emergency Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Association of State Policies With Per Capita Buprenorphine Treatment - 10 month(s) ago
This cross-sectional study uses US county-level pharmacy claims data to examine the association of selected state policies with rates of buprenorphine treatment.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1Buprenorphine Prescribing Not Contingent on Counseling, Other Services - 10 month(s) ago
Although supports such as counseling, case-management, and peer support are important parts of treatment plans for people with an opioid use disorder (OUD), providing buprenorphine should not be tied to their participation in those services, the US Food and Drug Administration (FDA) and Substance…
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Association of State Policies With Per Capita Buprenorphine Treatment - 10 month(s) ago
This cross-sectional study uses US county-level pharmacy claims data to examine the association of selected state policies with rates of buprenorphine treatment.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US - 10 month(s) ago
This cross-sectional study assesses the availability of buprenorphine for opioid use disorder treatment at local pharmacies in the US by state and retail pharmacy chain.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 4Changes in Waivered Clinicians Prescribing Buprenorphine and Prescription Volume by Patient Limit - 10 month(s) ago
This study uses data from a Drug Enforcement Administration list of Drug Addiction Treatment Act (DATA)–waivered clinicians to examine trends in DATA-waivered clinicians’ active participation in prescribing buprenorphine overall and by patient limits between January 2017 and May 2021.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 2Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity - 10 month(s) ago
This economic evaluation study includes a cost-effectiveness analysis and compares interventions associated with increased buprenorphine treatment initiation, duration, and capacity.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
"Most individuals with #opioid use disorders are still not on recommended medications." -- @ashleyleech, of @VUHealthPol, discussing how out-of-pocket costs remain a barrier to #buprenorphine use. @MedPagePsych https://t.co/zVzo8ot5fv